Scenario
Please read this scenario prior to answering the question
You are serving as the Lead Architect for an enterprise architecture project team within a leading
multinational pharmaceutical and medical devices manufacturer. Its brands include numerous
household names for medications and first aid supplies.
The company has a long history of innovating new treatments for many common illnesses and
diseases. Prior to launching a new treatment, the company has to demonstrate its effectiveness and
safety in a set of clinical trials that satisfy the regulatory requirements of the countries in the target
markets. All clinical trials are undertaken by its research laboratories, which employ over 10,000
people at separate facilities in the United Kingdom, United States, Sweden, France, Canada, India,
China and Japan. In addition to internal research and development activities the company is also
involved in publicly funded collaborative research projects, with other industrial and academic
partners.
The Enterprise Architecture group within the company has been engaged in an architecture
development project to create a secure networked collaboration system that will allow researchers
at its product development laboratories worldwide to share information about their clinical trials.
This system will also connect with external partners.
The Enterprise Architecture group is a mature organization. They use the TOGAF 9 ADM with
extensions required to support current good manufacturing practices and good laboratory practices
in their target markets. Due to the highly sensitive nature of the information that is managed, special
care was taken to ensure that each architecture domain included an examination of the security and
privacy issues that are relevant.
The Executive Vice President for Clinical Research is the sponsor of the Enterprise Architecture
activity. She has stated that the changes to the enterprise architecture for the new system will need
to be rolled out in stages on a regional basis that minimizes disruptions to ongoing clinical trials.
Refer to the Scenario
You have been asked to recommend the approach to identify the work packages that will be
included in the Transition Architecture(s).
Based on TOGAF, which of the following is the best answer?
A.
Determine the set of Solution Building Blocks required by identifying which Solution Building
Blocks need to be developed and which need to be procured. Eliminate any duplicate building
blocks. Group the remaining Solution Building Blocks together to create the work packages using a
CRUD matrix. Rank the work packages in terms of cost and select the most cost-effective options for
inclusion in a series of Transition Architectures. Schedule the roll out of the work packages to be
sequential across the geographic regions.
B.
Create an Implementation Factor Assessment and Deduction Matrix and a Consolidated Gaps,
Solutions and Dependencies Matrix. For each gap, identify a proposed solution and classify it as new
development, purchased solution, or based on an existing product. Group similar solutions together
to form work packages. Identify dependencies between work packages factoring in the clinical trial
schedules. Regroup the packages into a set of Capability Increments scheduled into a series of
Transition Architectures.
C.
Group the Solution Building Blocks from a Consolidated Gaps, Solutions and Dependencies Matrix
into a set of work packages. Using the matrix as a planning tool, regroup the work packages to
account for dependencies. Sequence the work packages into the Capability Increments needed to
achieve the Target Architecture. Schedule the rollout one region at a time. Document the
progression of the enterprise architecture using a state evolution table.
D.
Use a Consolidated Gaps, Solutions and Dependencies Matrix as a planning tool. For each gap
classify whether the solution is either a new envelopment, purchased solution, or based on an
existing product. Group the similar solutions together to define the work packages. Regroup the
work packages into a set of Capability Increments to transition to the Target Architecture taking into
account the schedule for clinical trials.